Rosuvastatin: What the Clinical Trials Actually Show
Rosuvastatin is one of the most potent statins available and one of the most thoroughly studied. It is also increasingly discussed in gyms, where people worry about cholesterol changes caused by diet, genetics or performance-enhancing drugs. Our editorial team summarises what the major trials found, where the drug did not help, and why it remains a prescription-only medicine.
What rosuvastatin is and how it works
Rosuvastatin belongs to the statin class. Statins block HMG-CoA reductase, the enzyme that controls a key step in cholesterol production in the liver. With less cholesterol made internally, liver cells increase the number of LDL receptors on their surface and pull more LDL ("bad") cholesterol out of the blood.
Compared with older statins, rosuvastatin is relatively hydrophilic and highly selective for liver tissue. It is also one of the most powerful on a milligram basis: at higher licensed doses it can reduce LDL cholesterol by around half, putting it alongside high-dose atorvastatin in the "high-intensity" category.
In the UK it is a prescription-only medicine. NICE guidance on cardiovascular risk has generally recommended atorvastatin as the first-line statin, but rosuvastatin is a common alternative, for instance when atorvastatin is not tolerated or a larger LDL reduction is needed.
The doses mentioned in this article are those used in published trials or in official product information. They are not recommendations. The decision to start a statin, and at what dose, depends on a full assessment of an individual's risk by a doctor.
JUPITER: primary prevention and the CRP question
The best-known rosuvastatin study is JUPITER, published in the New England Journal of Medicine in 2008. It enrolled nearly 18,000 people without known cardiovascular disease whose LDL cholesterol was not high but whose high-sensitivity C-reactive protein, a marker of inflammation, was raised.
Participants received 20 mg of rosuvastatin daily or placebo. The trial was stopped early, after a median of under two years, because the drug group had substantially fewer heart attacks, strokes and other major events; the relative reduction in the primary endpoint was in the region of 40–45 per cent.
JUPITER also showed a downside: physician-reported diabetes was modestly more common in the rosuvastatin group. Later analyses suggested that this risk was concentrated in people who already had risk factors for diabetes, and that the cardiovascular benefit still outweighed it overall.
Critics pointed out that the absolute risk in the study population was low, that the trial was stopped early, and that industry sponsorship may have influenced the design. These debates are useful reminders that relative risk reductions always need to be read alongside the starting risk.
Imaging studies and intermediate-risk populations
Several trials used imaging to test whether rosuvastatin could slow or reverse atherosclerosis. In ASTEROID (2006), 40 mg daily for two years was associated with a small regression of coronary plaque volume on intravascular ultrasound, alongside a large LDL reduction and a rise in HDL.
METEOR (2007) studied middle-aged people at low risk with thickened carotid artery walls. Rosuvastatin 40 mg slowed the progression of carotid intima-media thickness compared with placebo, although the trial was not designed to measure heart attacks or strokes.
HOPE-3 (2016) brought the question back to clinical events in a more ordinary population. Over 12,000 people at intermediate risk from many countries received 10 mg of rosuvastatin or placebo. After about five and a half years, the rosuvastatin group had significantly fewer major cardiovascular events.
Taken together with the Cholesterol Treatment Trialists' meta-analyses of all statin trials, these results support a consistent principle: the more LDL cholesterol is lowered, and the longer it stays lower, the greater the reduction in cardiovascular events.
Where rosuvastatin did not help
Not every trial was positive, and the negative ones are just as instructive. CORONA (2007) gave rosuvastatin 10 mg to older patients with established systolic heart failure. LDL fell as expected, but there was no significant reduction in the primary combined endpoint of cardiovascular death, heart attack or stroke.
AURORA (2009) studied people on haemodialysis. Again, LDL cholesterol dropped considerably, yet major cardiovascular events were not significantly reduced. In advanced kidney failure and heart failure, other disease processes seem to dominate, so lowering LDL alone has less impact.
| Trial (year) | Population | Daily dose studied | Main outcome |
|---|---|---|---|
| JUPITER (2008) | No CVD, raised hs-CRP | 20 mg | Fewer major events; trial stopped early |
| ASTEROID (2006) | Coronary artery disease | 40 mg | Small plaque regression on ultrasound |
| METEOR (2007) | Low risk, thickened carotid wall | 40 mg | Slower carotid thickening |
| HOPE-3 (2016) | Intermediate risk | 10 mg | Fewer major events |
| CORONA (2007) | Systolic heart failure | 10 mg | No significant benefit on primary endpoint |
| AURORA (2009) | Haemodialysis | 10 mg | No significant benefit on primary endpoint |
More recently, the Korean LODESTAR trial compared rosuvastatin with atorvastatin in patients with coronary disease. A secondary analysis published in the BMJ in 2023 found similar effectiveness for the main clinical outcomes, with rosuvastatin achieving lower LDL but being linked to slightly more new diabetes and cataract surgery.
The overall lesson is that rosuvastatin is a powerful LDL-lowering tool with proven benefit in primary and secondary prevention, but its value depends on the patient group. It is not a universal remedy for every condition that involves raised cholesterol.
Side effects and what active people should know
Most people tolerate statins well. Muscle aches are the most discussed side effect, yet blinded trials show that much of the reported muscle pain also occurs on placebo. Genuine myopathy and the rare but serious rhabdomyolysis are more likely at higher doses and with certain interacting drugs.
For people who train hard, it is worth knowing that intense or unaccustomed exercise itself raises creatine kinase. Doctors may ask patients to avoid heavy sessions for a few days before a CK blood test, so that exercise is not mistaken for drug-induced muscle damage.
Rosuvastatin levels in the blood are higher in people of East and South Asian heritage, which is why the official UK product information advises a lower starting dose in these groups. Kidney function, thyroid status, alcohol intake and other medicines, including ciclosporin and some antivirals, also influence safety.
Anabolic steroids often lower HDL and raise LDL cholesterol. Some users therefore try to self-medicate with statins obtained without a prescription. This is risky: it bypasses checks of liver function, interactions and genuine cardiovascular risk, and it does nothing to address other harms of steroid use.
Conclusions of the editorial team
Rosuvastatin has one of the largest evidence bases of any statin. JUPITER and HOPE-3 showed that it reduces cardiovascular events in people without established disease, and imaging studies showed slower or even reversed atherosclerosis at higher doses.
At the same time, CORONA and AURORA demonstrated that lowering LDL does not help every patient group. In established heart failure and dialysis, benefits on major outcomes were not proven, which is why individual assessment remains essential.
Side effects are usually mild, but diabetes risk, muscle symptoms and drug interactions need to be weighed by a doctor. Self-prescribing statins to offset the effects of performance-enhancing drugs is not a safe strategy.
If you want to explore this area further, our editorial team has also written about reading a lipid profile, the effects of anabolic steroids on cholesterol and heart health, and lifestyle measures that lower LDL cholesterol.
References
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
- Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
- Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297(12):1344–1353.
- Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–2031.
- Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261.
- Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Lee YJ, Hong SJ, Kang WC, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837.
